Streetbeat News

Analyst Ratings

NEE

RBC Capital analyst Shelby Tucker has reiterated an Outperform rating on NextEra Energy (NYSE:NEE) and maintained a price target of $74.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 3:11 pm

MSFT

Microsoft Corporation (NASDAQ:MSFT) is anticipated to report an increase in Q2 earnings with an expected $2.78 per share, up from $2.32 the previous year, and projected revenue of $61.10 billion. CEO Satya Nadella plans to visit India to explore AI opportunities. Shares rose 1.4% to $409.72. Analysts from Wedbush, Piper Sandler, BMO Capital, Mizuho, and Argus Research have reiterated positive ratings with price targets ranging from $420 to $455.

Portfolio Pulse from Avi Kapoor

January 30, 2024 | 3:09 pm

XEL

RBC Capital analyst Shelby Tucker has maintained a 'Sector Perform' rating on Xcel Energy (NASDAQ:XEL) and increased the price target from $67 to $68.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 3:08 pm

ZG

RBC Capital analyst Brad Erickson has maintained an Outperform rating on Zillow Group (NASDAQ:ZG) and increased the price target from $60 to $66.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 3:06 pm

APLS

Apellis Pharmaceuticals (NASDAQ:APLS) received diverse analyst ratings over the last three months, with 16 analysts offering evaluations. The average 12-month price target is $74.75, with a high of $106.00 and a low of $42.00, marking a 5.28% increase from the previous average of $71.00. Analysts from firms like Oppenheimer, Needham, and Goldman Sachs have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on the complement system. It has shown a revenue growth rate of 400.54% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -127.03%, ROE of -48.55%, and ROA of -16.18%.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 3:01 pm

MAXN

Maxeon Solar Technologies (NASDAQ:MAXN) received mixed analyst ratings with 3 bullish, 1 somewhat bullish, and 7 indifferent. The average 12-month price target is $9.45, down 39.03% from the previous target. Analysts from firms like Mizuho, Goldman Sachs, Morgan Stanley, UBS, Roth MKM, Northland Capital Markets, and Raymond James have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Maxeon is engaged in manufacturing and marketing solar technology, with a market cap below industry average, a negative revenue trend, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 3:00 pm

HLIT

Analysts have provided diverse opinions on Harmonic (NASDAQ:HLIT) with 5 bullish ratings in the past quarter. The average 12-month price target is $18.4, up from the previous $16.33. Analyst actions include maintaining and adjusting price targets, reflecting market conditions and company performance. Harmonic's financials show a revenue decline of -18.32% and below-average profitability metrics. The company's market cap is below industry benchmarks, and it has a conservative debt-to-equity ratio of 0.46.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 3:00 pm

WELL

Eight analysts have recently rated Welltower (NYSE:WELL), with a mix of bullish to bearish sentiments. The average 12-month price target is $98.62, up 8.21% from the previous $91.14. Analysts from firms like Deutsche Bank, Keybanc, and JP Morgan have raised their price targets, reflecting a positive outlook on Welltower's performance. The company has shown strong revenue growth and efficient asset management but faces challenges in profitability and equity capital usage. Welltower's diversified healthcare portfolio and conservative financial approach with a low debt-to-equity ratio are also highlighted.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 3:00 pm

RL

Eight financial analysts have recently updated their ratings for Ralph Lauren (NYSE:RL), with a mix of bullish and indifferent stances. The average 12-month price target has been raised to $144.25, up 8.3% from the previous $133.20. Analysts from firms like Raymond James, Wells Fargo, Goldman Sachs, TD Cowen, UBS, Telsey Advisory Group, and Evercore ISI Group have raised their price targets, indicating a positive outlook on the company's performance. Ralph Lauren's financials show a positive revenue trend, a high net margin, and strong ROE and ROA, with a prudent debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 3:00 pm

TPR

Analysts have mixed views on Tapestry (NYSE:TPR), with 9 ratings ranging from bullish to bearish. The average 12-month price target is $40.56, down from $47.29. Actions by analysts include both raised and lowered ratings and price targets. Tapestry, owning brands like Coach, Kate Spade, and Stuart Weitzman, has shown positive revenue growth and strong financial health indicators. The company plans to acquire Capri, adding brands like Michael Kors, Versace, and Jimmy Choo.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 3:00 pm